AL 53817

Drug Profile

AL 53817

Alternative Names: AL-53817

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Alcon
  • Class Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 11 Jul 2016 No recent reports on development identified - Phase-I for Seasonal allergic rhinitis in USA (Intranasal)
  • 11 Jul 2016 No recent reports on development identified - Phase-II for Allergic conjunctivitis in USA (Ophthalmic)
  • 01 Jul 2014 Alcon completes a phase II trial in Allergic conjunctivitis in USA (NCT02079649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top